Global GenAI study shows promise for health & life sciences

IntentTech Insights Staff Writer |
March, 2025

Generative AI is at the forefront of global innovation in both health care and life sciences. To better understand how technology is being used, data and AI leader SAS and Coleman Parkes Research conducted a global, cross-industry survey of 237 life sciences and pharma leaders and 240 health care leaders who are decision makers on their organization’s GenAI, data and analytics strategy.

Top IntentTech News: Schneider Electric Launches Future-Ready Modicon Edge I/O

New study reports how the health care and life sciences industries are implementing GenAI to improve business outcomes.

The study offers a deep dive into how these sectors are implementing GenAI, what their biggest challenges are and how health care and life sciences compares to industries like insurance, the public sector, banking, manufacturing and more.

Health care leans into GenAI innovation

The GenAI research for the health care sector revealed that leaders can envision the technology’s transformative ability and are optimistic about the potential for GenAI to support and complement the work of doctors, researchers and other health care professionals. More specifically:

46% of health care organizations currently use the technology, compared with 54% on average across all sectors.
Within the health care industry, 95% of organizations are already using or have plans to adopt GenAI within the next two years.
87% of health care organizations plan to invest in GenAI in the next financial year and 92% of those investing have a dedicated GenAI budget for the next year.
In organizations that have already integrated GenAI, the top measurable outcome is efficiency at processing large data sets (89%), followed by risk management and compliance measures (88%).

“The unique challenges and diverse functions of the health care sector demand special consideration to regulatory and compliance issues, data sensitivity, interoperability and bias in AI algorithms,” said Alyssa Farrell, Global Health and Life Sciences Industry Marketing Director at SAS. “The adoption of GenAI in health care is projected to rapidly catch up as the industry addresses these concerns.”